{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=177Lu-DOTATOC", "query": { "intervention": "177Lu-DOTATOC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=177Lu-DOTATOC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T03:46:08.018Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04082520", "title": "Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Meningioma", "Grade 2 Meningioma", "Grade 3 Meningioma", "Recurrent Meningioma", "Unresectable Meningioma" ], "interventions": [ { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-04-14", "completion_date": "2032-03-04", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082520" }, { "nct_id": "NCT04919226", "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT", "type": "DRUG" }, { "name": "CAPTEM (Capecitabine and Temozolomide)", "type": "DRUG" }, { "name": "Amino-Acid Solution", "type": "OTHER" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2021-12-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 14, "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919226" }, { "nct_id": "NCT01099228", "title": "Combination Targeted Radiotherapy in Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "131-I MIBG and 111-In pentetreotide", "type": "OTHER" }, { "name": "131-I MIBG and In-111 DOTATATE", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "David Bushnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2006-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-07-21", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 2, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01099228" }, { "nct_id": "NCT06441331", "title": "Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Somatostatin Receptor Positive", "NETs", "Lymphoma", "Solid Tumor", "CNS Tumors", "Rhabdomyosarcoma", "Peripheral Primitive Neuroectodermal Tumor", "GIST" ], "interventions": [ { "name": "Lutetium Lu 177-Edotreotide", "type": "DRUG" }, { "name": "Amino Acid Solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "24 Months to 18 Years" }, "enrollment_count": 20, "start_date": "2025-09-26", "completion_date": "2034-04", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 3, "location_summary": "San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06441331" }, { "nct_id": "NCT04609592", "title": "Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "Gallium 68 Dotatate", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-03-17", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04609592" }, { "nct_id": "NCT04276597", "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Neuroendocrine Neoplasm", "Pheochromocytoma", "Paraganglioma", "Thymus Carcinoid", "Unknown Primary Tumors", "Neuroendocrine Tumors", "Neuroendocrine Skin Carcinoma", "Neuroendocrine Breast Tumor", "Neuroendocrine Carcinoma Metastatic", "Neuroendocrine Neoplasm of Ovary" ], "interventions": [ { "name": "177Lu-DOTATOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Excel Diagnostics and Nuclear Oncology Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-04", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276597" }, { "nct_id": "NCT03923257", "title": "Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "177Lu-DOTA-tyr3-OCTREOTATE", "type": "DRUG" }, { "name": "Peptide Receptor Radiotherapy (PRRT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Year to 20 Years" }, "enrollment_count": 0, "start_date": "2020-08-04", "completion_date": "2021-06-03", "has_results": false, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03923257" }, { "nct_id": "NCT04529044", "title": "177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2026-06-30", "completion_date": "2027-12-20", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04529044" }, { "nct_id": "NCT07150546", "title": "Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Digestive System Neuroendocrine Tumor", "Unresectable Digestive System Neuroendocrine Neoplasm", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Digestive System Neuroendocrine Tumor G2" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2025-10-14", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07150546" }, { "nct_id": "NCT03049189", "title": "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-edotreotide PRRT", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Amino-Acid Solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2017-02-02", "completion_date": "2029-11", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-08T03:46:08.018Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049189" } ] }